Molecular mechanisms of cetuximab resistance in metastatic colorectal cancer
10.3760/cma.j.cn371439-20200208-00025
- VernacularTitle:转移性结直肠癌西妥昔单抗耐药的分子机制
- Author:
Hao SU
1
;
Wenjie LIU
;
Mandula BAO
;
Shou LUO
;
Xuewei WANG
;
Chuanduo ZHAO
;
Qian LIU
;
Xishan WANG
;
Zhixiang ZHOU
;
Haitao ZHOU
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科 100021
- From:
Journal of International Oncology
2020;47(5):308-311
- CountryChina
- Language:Chinese
-
Abstract:
Cetuximab has become an important molecular targeted drug for the treatment of metastatic colorectal cancer (mCRC), which increases the curative effect of chemotherapy and prolongs the survival time. However, some patients develop insensitiveness or resistance to cetuximab, while the complicated molecular mechanisms are not quite clear. With the deep research in epidermal growth factor receptor (EGFR) signaling pathway, the genetic alteration of KRAS, BRAF, PTEN and PIK3CA and polymorphism of microRNA (miRNA) have been proved to associated with cetuximab resistance. Wnt signaling pathway with its negative regulator RNF43 is also considered to be related with cetuximab resistance in recent studies. The review of the progress on molecular mechanisms of cetuximab resistance in mCRC can establish theoretical basis for finding out reasonable drugs to overcome the resistance.
